Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 11:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Osteoporosis, Postmenopausal
Interventions
Arzoxifene, Raloxifene
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Gainesville, Georgia • Urbandale, Iowa • Billings, Montana + 2 more
Conditions
Osteoporosis
Interventions
Raloxifene, Zoledronic acid, Placebo oral pills, Placebo intravenous (i.v.) infusion
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Phoenix, Arizona • Buena Park, California • Washington D.C., District of Columbia + 12 more
Conditions
Postmenopause
Interventions
Bazedoxifene 10 mg/CE 0.625 mg, Bazedoxifene 20 mg/CE 0.625 mg, Bazedoxifene 40 mg/CE 0.625 mg, Bazedoxifene 10 mg/CE 0.45 mg, Bazedoxifene 20 mg/CE 0.45 mg, Bazedoxifene 40 mg/CE 0.45 mg, Raloxifene 60 mg, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
Conditions
Osteoporosis
Interventions
lasofoxifene, raloxifene, Placebo
Drug
Lead sponsor
Ligand Pharmaceuticals
Industry
Eligibility
48 Years to 75 Years · Female only
Enrollment
540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
72
States / cities
Albany, California • Berkeley, California • La Jolla, California + 49 more
Conditions
BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms
Interventions
raloxifene, Finasteride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Breast Cancer
Interventions
Raloxifene, Tamoxifen
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
35 Years and older · Female only
Enrollment
19,747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
492
States / cities
Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 369 more
Conditions
Osteoporosis, Post-Menopausal
Interventions
raloxifene, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older · Female only
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
5
States / cities
La Jolla, California • Menlo Park, California • Oakland, California + 2 more
Conditions
Vasomotor Symptoms, Endometrial Safety
Interventions
Raloxifene, medroxyprogesterone acetate, estrogen, 17 beta estradiol
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years to 70 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Endometrial Cancer
Interventions
raloxifene
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Chicago, Illinois
Completed Phase 4 Interventional Accepts healthy volunteers

Estrogen Alternatives Study

NCT00108238
Conditions
Healthy
Interventions
Estradiol followed by progesterone, Raloxifene
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Polycystic Ovarian Syndrome
Interventions
Raloxifene, Clomiphene
Drug
Lead sponsor
Bruce Lessey
Other
Eligibility
18 Years to 36 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Greenville, South Carolina
Completed No phase listed Observational Results available

Study Evaluating Changes In Mammographic Breast Density

NCT00774267
Conditions
Osteoporosis
Interventions
BZA 20 mg/CE 0.45 mg, BZA 20 mg/CE 0.625 mg, Raloxifene 60 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
Conditions
Urinary Bladder Neoplasms
Interventions
Tamoxifen
Drug
Lead sponsor
Seth Lerner
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Conditions
Osteoporosis, Postmenopausal
Interventions
Risedronate, Raloxifene, Placebo
Drug · Other
Lead sponsor
Sanofi
Industry
Eligibility
Up to 65 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Breast Cancer
Interventions
Sample collection, Patient-reported outcomes
Other · Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Cognition in the Study of Tamoxifen and Raloxifene

NCT00687102
Conditions
Cognition, Aging
Interventions
tamoxifen, raloxifene
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
65 Years and older · Female only
Enrollment
1,498 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2008
U.S. locations
127
States / cities
Phoenix, Arizona • Tucson, Arizona • Camp Pendleton, California + 102 more
Conditions
Breast Cancer
Interventions
Raloxifene - Usual, Raloxifene - Study
Drug
Lead sponsor
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Industry
Eligibility
24 Years to 64 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rockville, Maryland
Conditions
Metastatic Breast Cancer
Interventions
17B-estradiol, Letrozole, Anastrozole, Exemestane
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Springfield, Massachusetts • Rochester, Minnesota • Lebanon, New Hampshire
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 63 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
10
States / cities
San Diego, California • Upland, California • Meridian, Idaho + 7 more
Conditions
Breast Cancer, Xerostomia
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Osteoporosis, Post-Menopausal
Interventions
Raloxifene, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
2
States / cities
Indianapolis, Indiana • Omaha, Nebraska
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Stage IV Prostate Cancer
Interventions
bicalutamide, raloxifene, quality-of-life assessment
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Scottsdale, Arizona
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake

NCT02517593
Conditions
Breast Cancer
Interventions
Polygenic Risk Score
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
151 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Osteoporosis
Interventions
Bazedoxifene Acetate, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 80 Years · Female only
Enrollment
7,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
205
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 141 more